CFDA 93.853: Extramural Research Programs in Neurosciences and Neurological Disorders
NINDS's primary CFDA for neuroscience and neurological-disorders research. Covers everything from basic neuroscience to clinical trials in stroke, ALS, Parkinson's, MS, epilepsy, traumatic brain injury, and more.
What this CFDA funds
Basic neuroscience research, translational studies, clinical trials in neurological disorders, clinical research networks (StrokeNet, NeuroNEXT), research training (T32, F-series, K-series), and strategic initiatives like the BRAIN Initiative and HEAL (Helping to End Addiction Long-term).
What winning applicants look like
Tier-1 research universities and AAU member institutions. NINDS also explicitly funds community-engaged research and health-disparities work in stroke and TBI — these awards have lower competitive pressure than mainstream R01s. Pediatric neurology and rare-disease research has dedicated funding streams.
Common pitfalls + things to know
NIH Stage Model framework applies to clinical-trial proposals — Stage 1 (intervention generation) vs Stage 2 (efficacy testing) vs Stage 3 (effectiveness in real-world settings) determines required design rigor. Specific Aims for translational research must clearly articulate clinical relevance.
Related CFDAs to also explore
- CFDA 93.310 — Trans-NIH Research Support
- CFDA 93.398 — Cancer Research
- CFDA 93.866 — Aging Research
Always verify in the official source. CFDA program details, eligibility, and award ranges change with each annual NOFO cycle. Confirm at sam.gov/content/assistance-listings or the agency's program office before you build an application strategy. This page is editorial reference, not an official agency notice.